[an error occurred while processing this directive] | [an error occurred while processing this directive]
Clinical value and research progress on multimodal radiological and radiomic examinations in evaluating the clinical efficacy of chemoradiotherapy for esophageal cancer
Han Weiming, Xiao Zefen
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Abstract With the development of radiology, it has been found that clinical radiological examinations can provide evidence for evaluating the clinical efficacy of chemoradiotherapy for esophageal cancer. In this article, the clinical values of various radiological and radiomic examinations in predicting the clinical prognosis of esophageal cancer patients treated with chemoradiotherapy were reviewed and discussed.
Han Weiming,Xiao Zefen. Clinical value and research progress on multimodal radiological and radiomic examinations in evaluating the clinical efficacy of chemoradiotherapy for esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2020, 29(7): 583-588.
Han Weiming,Xiao Zefen. Clinical value and research progress on multimodal radiological and radiomic examinations in evaluating the clinical efficacy of chemoradiotherapy for esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2020, 29(7): 583-588.
[1] van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012, 366(22):2074-2084. DOI:10.1056/NEJMoa1112088. [2] Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS):long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015, 16(9):1090-1098. DOI:10.1016/S1470-2045(15)00040-6. [3] Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010):A phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018, 36(27):2796-2803. DOI:10.1200/JCO.2018.79.1483. [4] 欧广飞, 汪楣, 王绿化, 等. 食管癌术前放疗后病理反应与预后的关系[J]. 中华肿瘤杂志, 2003, 25(3):278-281. DOI:10.3760/j.issn:0253-3766.2003.03.021. Ou GF, Wang M, Wang LH, et al. Relation between pathologic tumor response to preoperative radiotherapy and the prognosis in patients with esophageal carcinoma[J]. Chin J Oncol, 2003, 25(3):278-81. DOI:10.3760/j.issn:0253-3766.2003.03.021. [5] den Bakker CM, Smit JK, Bruynzeel AME, et al. Non responders to neoadjuvant chemoradiation for esophageal cancer: why better prediction is necessary[J]. J Thorac Dis, 2017, 9(Suppl 8): S843-S850. DOI: 10.21037/jtd.2017.06.123. [6] Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus[J]. J Clin Oncol, 2005, 23(10):2310-2317. DOI:10.1200/JCO.2005.00.034. [7] Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus:FFCD 9102[J]. J Clin Oncol, 2007, 25(10):1160-1168. DOI:10.1200/JCO.2005.04.7118. [8] Swisher SG, Moughan J, Komaki RU, et al. Final results of NRG oncology RTOG 0246:An organ-preserving selective resection strategy in esophageal cancer patients treated with definitive chemoradiation[J]. J Thorac Oncol, 2017, 12(2):368-374. DOI:10.1016/j.jtho.2016.10.002. [9] Taketa T, Xiao L, Sudo K, et al. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation[J]. Oncology, 2013, 85(2):95-99. DOI:10.1159/000351999. [10] Castoro C, Scarpa M, Cagol M, et al. Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus:is surgery always necessary?[J]. J Gastrointest Surg, 2013, 17(8):1375-1381. DOI:10.1007/s11605-013-2269-3. [11] Rohatgi PR, Swisher SG, Correa AM, et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus[J]. Cancer, 2005, 104(7):1349-1355. DOI:10.1002/cncr.21346. [12] Kim MK, Kim SB, Ahn JH, et al. Treatment outcome and recursive partitioning analysis-based prognostic factors in patients with esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy[J]. Int J Radiat Oncol Biol Phys, 2008, 71(3):725-734. DOI:10.1016/j.ijrobp.2007.10.009. [13] Meguid RA, Hooker CM, Taylor JT, et al. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer:does the pattern of recurrence differ for patients with complete response and those with partial or no response?[J]. J Thorac Cardiovasc Surg, 2009, 138(6):1309-1317. DOI:10.1016/j.jtcvs.2009.07.069. [14] Tong DK, Law S, Kwong DL, et al. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor[J]. J Annals of Surgical Oncology, 2010, 17(8):2184-2192. DOI:10.1245/s10434-010-0995-2. [15] Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival[J]. J Clin Oncol, 2005, 23(19):4330-4337. DOI:10.1200/JCO.2005.05.017. [16] Semenkovich TR, Meyers BF. Surveillance versus esophagectomy in esophageal cancer patients with a clinical complete response after induction chemoradiation[J]. Ann Transl Med, 2018, 6(4):81. DOI:10.21037/atm.2018.01.31. [17] Liu SL, Xi M, Yang H, et al. Is there a correlation between clinical complete response and pathological complete response after neoadjuvant chemoradiotherapy for esophageal squamous cell cancer?[J]. Ann Surg Oncol, 2016, 23(1):273-281. DOI:10.1245/s10434-015-4764-0. [18] Chao YK, Tseng CK, Wen YW, et al. Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy[J]. Ann Surg Oncol, 2013, 20(9):3000-3008. DOI:10.1245/s10434-013-2962-1. [19] Monjazeb AM, Riedlinger G, Aklilu M, et al. Outcomes of patients with esophageal cancer staged with[(1)(8) F]fluorodeoxyglucose positron emission tomography (FDG-PET):can postchemoradiotherapy FDG-PET predict the utility of resection?[J]. J Clin Oncol, 2010, 28(31):4714-4721. DOI:10.1200/JCO.2010.30.7702. [20] 万钧, 肖爱勤, 高淑珍, 等. 食管癌放疗后近期疗效评价标准——附1000例分析[J]. 中国放射肿瘤学,1989,3(4):3-5. Wan J, Xiao AQ, Gao SZ, et al. Criteria of evaluation of immediate response of radiation therapy for esophageal carcinoma-report on 1000 patients[J]. Chin J Radiat Oncol, 1989, 3(4):3-5. [21] Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada[J]. J Natl Cancer Inst, 2000, 92(3):205-216. DOI:10.1093/jnci/92.3.205. [22] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247. DOI:10.1016/j.ejca.2008.10.026. [23] Tsurumaru D, Hiraka K, Komori M, et al. Role of barium esophagography in patients with locally advanced esophageal cancer:evaluation of response to neoadjuvant chemoradiotherapy[J]. Radiol Res Pract, 2013, 2013:502690. DOI:10.1155/2013/502690. [24] Kurokawa Y, Shibata T, Ando N, et al. Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer:RECIST or histology?[J]. Ann Surg Oncol, 2013, 20(9):3009-3014. DOI:10.1245/s10434-013-2946-1. [25] Chen Y, Zhang Z, Jiang G, et al. Gross tumor volume is the prognostic factor for squamous cell esophageal cancer patients treated with definitive radiotherapy[J]. J Thorac Dis, 2016, 8(6):1155-1161. DOI:10.21037/jtd.2016.04.08. [26] van Rossum PS, van Lier AL, van Vulpen M, et al. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer[J]. Radiother Oncol, 2015, 115(2):163-170. DOI:10.1016/j.radonc.2015.04.027. [27] Heethuis SE, van Rossum PS, Lips IM, et al. Dynamic contrast-enhanced MRI for treatment response assessment in patients with oesophageal cancer receiving neoadjuvant chemoradiotherapy[J]. Radiother Oncol, 2016, 120(1):128-135. DOI:10.1016/j.radonc.2016.05.009. [28] van Heijl M, Omloo JM, van Berge-Henegouwen MI, et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer[J]. Ann Surg, 2011, 253(1):56-63. DOI:10.1097/SLA.0b013e3181f66596. [29] Kim SJ, Koo PJ, Chang S. Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients[J]. Cancer Chemother Pharmacol, 2016, 77(4):723-731. DOI:10.1007/s00280-016-2988-8. [30] Miyata H, Yamasaki M, Takiguchi S, et al. Prognostic value of endoscopic biopsy findings after induction chemoradiotherapy with and without surgery for esophageal cancer[J]. Ann Surg, 2011, 253(2):279-284. DOI:10.1097/SLA.0b013e318206824f. [31] van Rossum PS, Goense L, Meziani J, et al. Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer:a systematic review and meta-analysis[J]. Gastrointest Endosc, 2016, 83(5):866-879. DOI:10.1016/j.gie.2015.11.026. [32] Goense L, Heethuis SE, van Rossum PSN, et al. Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer[J]. Nucl Med Commun, 2018, 39(1):60-67. DOI:10.1097/MNM.0000000000000771. [33] Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO):a prospective multicentre, diagnostic cohort study[J]. Lancet Oncol, 2018, 19(7):965-974. DOI:10.1016/S1470-2045(18)30201-8. [34] Noordman BJ, Wijnhoven BPL, Lagarde SM, et al. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer:a stepped-wedge cluster randomised trial[J]. BMC Cancer, 2018, 18(1):142. DOI:10.1186/s12885-018-4034-1. [35] Borggreve AS, Mook S, Verheij M, et al. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE):a multicenter observational study[J]. BMC Cancer, 2018, 18(1):1006. DOI:10.1186/s12885-018-4892-6. [36] 韩春, 任雪姣, 王澜, 等. 钡餐造影结合CT评价食管癌放疗近期疗效的研究[J]. 中华放射肿瘤学杂志, 2013, 22(1):26-29. DOI:10.3760/cma.j.issn.1004-4221.2013.01.008. Han C, Ren XJ, Wang L, et al. Evaluating short-term radiotherapeutic effect on esophageal cancer by barium meal combined with CT scans[J]. Chin J Radiat Oncol, 2013, 22(1):26-29. DOI:10.3760/cma.j.issn.1004-4221.2013.01.008. [37] Qiu B, Wang D, Yang H, et al. Combined modalities of magnetic resonance imaging, endoscopy and computed tomography in the evaluation of tumor responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma[J]. Radiother Oncol, 2016, 121(2):239-245. DOI:10.1016/j.radonc.2016.09.017. [38] Heneghan HM, Donohoe C, Elliot J, et al. Can CT-PET and endoscopic assessment post-neoadjuvant chemoradiotherapy predict residual disease in esophageal cancer?[J]. Ann Surg, 2016, 264(5):831-838. DOI:10.1097/SLA.0000000000001902. [39] Fang P, Musall BC, Son JB, et al. Multimodal imaging of pathologic response to chemoradiation in esophageal cancer[J]. Int J Radiat Oncol Biol Phys, 2018, 102(4):996-1001. DOI:10.1016/j.ijrobp.2018.02.029. [40] Tan S, Kligerman S, Chen W, et al. Spatial-temporal[(1)(8) F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy[J]. Int J Radiat Oncol Biol Phys, 2013, 85(5):1375-1382. DOI:10.1016/j.ijrobp.2012.10.017. [41] Yip C, Landau D, Kozarski R, et al. Primary esophageal cancer:heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy[J]. Radiology, 2014, 270(1):141-148. DOI:10.1148/radiol.13122869. [42] Riyahi S, Choi W, Liu CJ, et al. Quantifying local tumor morphological changes with Jacobian map for prediction of pathologic tumor response to chemo-radiotherapy in locally advanced esophageal cancer[J]. Phys Med Biol, 2018, 63(14):145020. DOI:10.1088/1361-6560/aacd22. [43] Larue R, Klaassen R, Jochems A, et al. Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer[J]. Acta Oncol, 2018, 57(11):1475-1481. DOI:10.1080/0284186X.2018.1486039. [44] Zhang YH, Herlin G, Rouvelas I, et al. Texture analysis of computed tomography data using morphologic and metabolic delineation of esophageal cancer-relation to tumor type and neoadjuvant therapy response[J]. Dis Esophagus, 2019, 32(4):doy096. DOI:10.1093/dote/doy096. [45] Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics:extracting more information from medical images using advanced feature analysis[J]. Eur J Cancer, 2012, 48(4):441-446. DOI:10.1016/j.ejca.2011.11.036. [46] Bi WL, Hosny A, Schabath MB, et al. Artificial intelligence in cancer imaging:Clinical challenges and applications[J]. CA Cancer J Clin, 2019, 69(2):127-157. DOI:10.3322/caac.21552. [47] Verma V, Simone CB 2nd, Krishnan S, et al. The rise of radiomics and implications for oncologic management[J]. J Natl Cancer Inst, 2017, 109(7). DOI:10.1093/jnci/djx055. [48] van Rossum PSN, Xu C, Fried DV, et al. The emerging field of radiomics in esophageal cancer:current evidence and future potential[J]. Transl Cancer Res, 2016, 5(4):410-423. DOI:10.21037/tcr.2016.06.19. [49] Zhang Q, Xiao Y, Suo J, et al. Sonoelastomics for breast tumor classification:a radiomics approach with clustering-based feature selection on sonoelastography[J]. Ultrasound Med Biol, 2017, 43(5):1058-1069. DOI:10.1016/j.ultrasmedbio.2016.12.016. [50] Qiao M, Hu Y, Guo Y, et al. Breast tumor classification based on a computerized breast imaging reporting and data system feature system[J]. J Ultrasound Med, 2018, 37(2):403-415. DOI:10.1002/jum.14350. [51] Gillies RJ, Kinahan PE, Hricak H. Radiomics:images are more than pictures, they are data[J]. Radiology, 2016, 278(2):563-577. DOI:10.1148/radiol.2015151169.
2020, Vol. 29 
